Korea's Chemizon Inks Drug Development Deal with China's Shenogen Pharma
This article was originally published in PharmAsia News
SEOUL - South Korean Optomagic subsidiary Chemizon signed a drug development cooperation agreement with China's Shenogen Pharma Group for small molecule therapeutics targeting modulators of the estrogen receptor alpha 36
You may also be interested in...
Shenogen is a startup aimed at discovery and development of small molecule and biologic drugs targeted at a novel estrogen receptor (ER) variant discovered and characterized by the company. Its leading compound SNG-162 (icaritin) is in Phase II clinical trials in China.
SHANGHAI - Chemizon received board approval to invest $5 million in 2008 in its Beijing-based subsidiary, the company announced Aug. 6
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).